Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ELUTIA INC. (ELUT)

Elutia closes $7.7 million SimpliDerm sale to Cellution Biologics

Mixed Impact 4 of 5 m&a Written later

Elutia completed the sale of its SimpliDerm breast reconstruction business, which made up substantially all of its Women's Health segment, to Cellution Biologics on August 17, 2026. The company received $7.7 million in cash at closing, subject to post-closing adjustments, with up to $3 million more in contingent payments. The filing says the company's 2025 and first-half 2026 pro forma continuing operations exclude the business, which had accounted for most of its reported net sales.

Key points

  • Net cash received at closing: $7.7 million, subject to post-closing inventory adjustments
  • Contingent payments of up to $3 million over the next 18 months, tied to technology transfer and commercial milestones
  • Pro forma six-month 2026 net sales from continuing operations: $2.2 million, versus $5.5 million as reported
  • Company expects to record an estimated gain of $4.9 million, which is not reflected in the pro forma periods

The filing

CompanyELUTIA INC. (ELUT)
Form8-K, current report
Filed with the SECAug 21, 2026, 5:00 PM ET
Accession number0001104659-26-099731

Items reported: 2.01 Acquisition or Disposition Completed7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 21, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.